OptiNose, Inc. (OPTN) News
Filter OPTN News Items
OPTN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPTN News Highlights
- OPTN's 30 day story count now stands at 2.
- Over the past 14 days, the trend for OPTN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, DRUG and EAR are the most mentioned tickers in articles about OPTN.
Latest OPTN News From Around the Web
Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCEThe application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused |
Optinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceYARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the |
Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),Key Insights Institutions' substantial holdings in OptiNose implies that they have significant influence over the... |
OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call TranscriptOptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript November 9, 2023 OptiNose, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […] |
OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating EfficiencyKey Financial Highlights and Operational Updates |
Optinose Reports Third Quarter 2023 Financial Results and Operational UpdatesCompany reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients tr |
Optinose Announces Reporting Date for Third Quarter 2023 Financial ResultsConference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern TimeYARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023. Company to Host Conference CallMembers of the Company’s leadership team will hos |
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Investors in OptiNose (NASDAQ:OPTN) have unfortunately lost 87% over the last five yearsWhile it may not be enough for some shareholders, we think it is good to see the OptiNose, Inc. ( NASDAQ:OPTN ) share... |
Optinose to Present at the 2023 Cantor Global Healthcare ConferenceYARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcas |